119293-22-0

Basic information

• Product Name: 3-Hydroxyfuro[3,2-c]pyridine-2-carboxylic acid ethyl ester
• Synonyms: 3-Hydroxyfuro[3,2-c]pyridine-2-carboxylic acid ethyl ester;ethyl 3-hydroxyfuro[3,2-c]pyridine-2-carboxylate
• CAS NO: 119293-22-0
• Molecular Formula: C₁₀H₉NO₄
• Molecular Weight: 207
• EINECS: -0
• Mol File: 119293-22-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Hydroxyfuro[3,2-c]pyridine-2-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxyfuro[3,2-c]pyridine-2-carboxylic acid ethyl ester(119293-22-0)
• EPA Substance Registry System: 3-Hydroxyfuro[3,2-c]pyridine-2-carboxylic acid ethyl ester(119293-22-0)

Safety Data

• Hazardous Substances Data: 119293-22-0(Hazardous Substances Data)

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 10177-29-4 4-chloronicotinic acid 
• 75-03-6 ethyl iodide 
• 37831-62-2 ethyl 4-chloronicotinate 

Downstream Products

• 1009334-22-8 3-(2-fluoro-4-nitro-phenoxy)-furo[3,2-c]pyridine-2-carboxylic acid ethyl ester 
• 119293-04-8 5-Azacumaran-3-on 
• 1009333-67-8 ethyl 3-(4-trimethylsilyl-2-fluoro-phenylamino)-furo[3,2-c]pyridine-2-carboxylate 
• 1009333-61-2 ethyl 3-(2-fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylate 
• 1009335-01-6 C₁₄H₈FIN₂O₃ 

Relevant articles and documents

Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models

Although mitogen-activated protein (MAP)-extracellular signal-regulated kinase (ERK) kinase (MEK) inhibition is predicted to cause cell death by stabilization of the proapoptotic BH3-only protein BIM, the induction of apoptosis is often modest. To determine if addition of a Bcl-2 family inhibitor could increase the efficacy of a MEK inhibitor, we evaluated a panel of 53 non-small cell lung cancer and pancreatic cancer cell lines with the combination of navitoclax (ABT-263), a Bcl-2/Bcl-xL (BCL2/BCL2L1) antagonist, and a novel MAP kinase (MEK) inhibitor, G-963. The combination is synergistic in the majority of lines, with an enrichment of cell lines harboring KRAS mutations in the high synergy group. Cells exposed to G-963 arrest in G1 and a small fraction undergo apoptosis. The addition of navitoclax to G-963 does not alter the kinetics of cell-cycle arrest, but greatly increases the percentage of cells that undergo apoptosis. The G-963/navitoclax combination was more effective than either single agent in the KRAS mutant H2122 xenograft model; BIM stabilization and PARP cleavage were observed in tumors, consistent with the mechanism of action observed in cell culture. Addition of the phosphatidylinositol 3-kinase (PI3K, PIK3CA) inhibitor GDC-0941 to this treatment combination increases cell killing compared with double- or single-agent treatment. Taken together, these data suggest the efficacy of agents that target the MAPK and PI3K pathways can be improved by combination with a Bcl-2 family inhibitor.

SPIROFUROPYRIDINE ARYL DERIVATIVES

Compounds of formula (I): and pharmaceutically-acceptable salts thereof, wherein: Ar is a moiety of formula (II) or (III): and A, B, and R1 are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.